Steve Cockrill leads Analytical Development and Quality Control at Akero Therapeutics. Prior to Akero, Steve served as Executive Director of Drug Substance Development, Analytical Development, and Quality Control organizations at Assembly Biosciences, where he established internal functional capabilities for microbiome therapeutics. His responsibilities included strategic and tactical direction of process development, method lifecycle management, product characterization, GMP testing for in-process, release, and stability studies, and CMC activities in support of regulatory filings. Additionally, he directed activities at domestic and international CRO and CDMO partners for scale up and GMP production of Drug Substance clinical supply.
Steve’s previous responsibilities included establishment and direction of Analytical Development and Quality Control functions at Ophthotech (now Iveric Bio) for commercialization of PEGylated oligonucleotide compounds targeting age-related macular degeneration. Prior to Ophthotech, he led strategic efforts to develop and optimize analytical strategies and global implementation of technologies to support Amgen’s future state aspirations for Quality Control.
Before joining Corporate Quality Control at Amgen, Steve provided oversight of commercialization activities for late-stage biologic therapeutics as a lead in Analytical Sciences and functional representative on process teams. His role included direction of a group of scientists responsible for primary structure characterization and mass analysis, including post-translational modification. In addition, Steve played a pivotal role in establishing analytical strategies for late-stage recombinant protein therapeutics through commercialization and post-marketing support, impacting several blockbuster therapies including Aranesp, Epogen, Neupogen/Neulasta, Enbrel, Vectibix, Nplate, and Prolia/XGEVA.
Steve earned a Ph.D. in Chemistry from Texas A&M University and a B.Sc. in Chemistry from the University of York, England.